Orthocell sees four patients benefit from CelGro trial

Company News

by Rachael Jones

Regenerative medicine company Orthocell (ASX:OCC) have seen the first four patients successfully complete participation in the CelGro® nerve regeneration clinical trial.

Following surgery with CelGro®, patients have regained muscle function and/or sensation of affected limbs and have returned to work, sport and activities of daily living.

The patients had previously suffered traumatic peripheral nerve injuries following motor vehicle, sporting and work-related incidents, resulting in complete paralysis, or impaired use of the upper limb.

Shares in Orthocell (ASX:OCC) closed flat at 11.5 cents yesterday.


Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.